공시 • Mar 27
Essity AB (Publ) Approves Dividend for the Financial Year 2025 Essity AB (publ) at its Annual General Meeting held on March 26, 2026 declared a dividend for the financial year 2025 of SEK 8.75 per share. Record date for the dividend is set to March 30, 2026. 공시 • Mar 03
Essity Announces Executive Changes Essity has appointed Niklas Westin Sundberg as Chief Digital & Information Officer. He will succeed Carl-Magnus Månsson, who is leaving Essity to take up a new external role. Niklas will become a member of the Executive Management Team and be responsible for the company's continued digital transformation and the Digital Transformation and Business Enablement function. With more than 20 years of experience in digital development in international and complex organizations, Niklas Westin Sundberg has led business-driven IT strategies, cybersecurity work and AI initiatives at global companies such as Kuehne+Nagel and ASSA ABLOY. Niklas Westin Sundberg will take office on April 15, 2026 and will report directly to Ulrika Kolsrud, President and CEO of Essity. 공시 • Feb 03
Essity AB (publ) (OM:ESSITY B) completed the acquisition of Feminine care business from Edgewell Personal Care Company (NYSE:EPC). Essity AB (publ) (OM:ESSITY B) entered into a definitive agreement to acquire Feminine care business from Edgewell Personal Care Company (NYSE:EPC) for $340 million on November 12, 2025. The feminine care business includes Playtex®, Stayfree®, Carefree® and o.b.® and Edgewell Personal Care Company will classify the Feminine Care business as discontinued operations in the beginning of first quarter of 2026. Pursuant to the terms of the Purchase Agreement, the Edgewell Personal Care Company is entitled to receive a termination fee of $15 million from Essity AB. if the Purchase Agreement is terminated under certain circumstances.
The transaction is expected to close in the first quarter of calendar 2026, subject to customary closing conditions, including the receipt of required regulatory approvals. Edgewell Personal Care Company intends to use the net proceeds from the sale, after taxes and transaction costs, primarily to strengthen its balance sheet while continuing to invest in the long-term growth of its core businesses.
Latham & Watkins LLP acted as legal advisor and Perella Weinberg Partners LP acted as financial advisor for Edgewell Personal Care Company. Morgan Stanley AB acted as financial advisor to Essity AB (publ).
Essity AB (publ) (OM:ESSITY B) completed the acquisition of Feminine care business from Edgewell Personal Care Company (NYSE:EPC) on February 2, 2026. 공시 • Jan 08
Funds Discontinue Legal Action Against Essity over Bond Loans in English Courts The funds that have brought an action against Essity in the English courts regarding bond loans issued by the company have chosen to discontinue their action. The case is therefore closed. On October 17, 2024, Essity announced that the company had received a request for early redemption from certain investors regarding bonds maturing in 2029, 2030 and 2031, respectively. In December 2024, the funds initiated proceedings against Essity in the English courts. The parties have entered into an agreement with conditions, among other things, that they have no claims against each other due to Essity's sale of its shares in Vinda. The funds subsequently discontinued their action before the court. Essity has not changed its view that the action was unfounded and has not paid the funds or otherwise compensated them in the dispute. 공시 • Nov 13
Essity AB (publ) (OM:ESSITY B) entered into a definitive agreement to acquire Feminine care business from Edgewell Personal Care Company (NYSE:EPC) for $340 million. Essity AB (publ) (OM:ESSITY B) entered into a definitive agreement to acquire Feminine care business from Edgewell Personal Care Company (NYSE:EPC) for $340 million on November 12, 2025. The feminine care business includes Playtex®, Stayfree®, Carefree® and o.b.® and Edgewell Personal Care Company will classify the Feminine Care business as discontinued operations in the beginning of first quarter of 2026 and intends to use the net proceeds from the sale, after taxes and transaction costs, primarily to strengthen its balance sheet while continuing to invest in the long-term growth of its core businesses. Pursuant to the terms of the Purchase Agreement, the Company is entitled to receive a termination fee of $15 million from Essity AB. if the Purchase Agreement is terminated under certain circumstances
The transaction is expected to close in the first quarter of calendar 2026, subject to customary closing conditions, including the receipt of required regulatory approvals.
Latham & Watkins LLP acted as legal advisor and Perella Weinberg Partners LP acted as financial advisor for Edgewell Personal Care Company. Morgan Stanley AB acted as financial advisor to Essity AB (publ). 공시 • Sep 20
Donato Giorgio Leaves as President Global Supply Chain and Member of the Executive Management Team of Essity, Effective October 31, 2025 Essity announced that Donato Giorgio, President Global Supply Chain and member of the Executive Management Team, will leave the company. Donato Giorgio joined Essity in 2009 and has held various leadership positions within Essity's global manufacturing and supply chain. In 2015, he became a member of the Executive Management Team and under his leadership, the company has developed its sustainable manufacturing and circular resource solutions. Donato Giorgio will leave his position on October 31, 2025. The recruitment process for his successor has been initiated. 공시 • Aug 16
Essity Appoints Anand Chandarana as President of Business Unit Health & Medical, Effective from September 1, 2025 Essity announced appointment ofAnand Chandarana as President of Business Unit Health & Medical. He will assume the role on September 1, 2025, and will also join the company’s Executive Management Team. Anand Chandarana has been with Essity and the business unit Health & Medical since 2020, most recently as Vice President Commercial Development. He has previously worked 17 years and held several senior positions at the medical solutions company Mölnlycke Health Care. Anand Chandarana will report to Ulrika Kolsrud, President and CEO of Essity. He is a citizen of both the UK and Sweden and will be based in Gothenburg. Business Unit Health & Medical offers products and solutions under the categories Incontinence Products Health Care, Wound Care, Compression therapy and Orthopedics under leading brands such as TENA, Leukoplast, Cutimed, Hydrofera BLUE, JOBST, Delta-Cast, and Actimove. Board Change • Aug 14
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Director Katarina Martinson was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Board Change • Jun 23
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Director Katarina Martinson was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. 공시 • Apr 29
Essity AB (publ) (OM:ESSITY B) commences an Equity Buyback Plan for 60,946,249 shares, representing 8.79% of its issued share capital, under the authorization approved on March 27, 2025. Essity AB (publ) (OM:ESSITY B) commences share repurchases on April 24, 2025, under the program mandated by the shareholders in the Annual General Meeting held on March 27, 2025. As per the mandate, the company is authorized to repurchase up to 60,946,249 B shares, representing 8.79% of its issued share capital. The shares shall be repurchased such that the company does not hold more than 10% of its issued share capital. The shares will be repurchased at a price on Nasdaq Stockholm at a price within the at each time prevailing price interval for the share on the marketplace, meaning the interval between the highest purchase price and the lowest selling price. The purpose of the proposed authorization is to be able to adapt the company’s capital structure. The repurchased shares will be used as payment or financing on account of acquisitions of companies or businesses, and thereby contribute to increased shareholder value. The program will be valid until the Annual General Meeting in 2026. As of February 20, 2025, the company had 702,342,489 issued shares consisting of 58,973,654 are class A shares and 643,368,835 are class B shares including 9,288,000 B shares in treasury.
On April 23, 2025, the company announced a share repurchase program. Under the program, the company will repurchase up to SEK 3,000 million worth of its B shares. The repurchased shares are expected to be cancelled. The share repurchase will be financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of the company’s capital allocation. The repurchases will commence from April 24, 2025, and will be valid till Annual General Meeting of 2026. 공시 • Mar 24
Essity AB (publ) to Report Q1, 2025 Results on Apr 24, 2025 Essity AB (publ) announced that they will report Q1, 2025 results at 7:00 AM, Central European Standard Time on Apr 24, 2025 공시 • Feb 22
Essity AB (publ), Annual General Meeting, Mar 27, 2025 Essity AB (publ), Annual General Meeting, Mar 27, 2025, at 14:00 W. Europe Standard Time. Location: at stockholm waterfront congress centre, nils ericsons plan 4, stockholm Sweden 
